How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: In the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial involving 7,020 patients with type 2 diabetes and established cardiovascular (CV) disease, empagliflozin given in addition to standard of care reduced the risk of CV death by 38% versus placebo (hazard ratio [HR] 0.62 [95% CI 0.49, 0.77]). This exploratory mediation analysis assesses the extent to which treatment group differences in covariates during the trial contributed to CV death risk reduction with empagliflozin. RESEARCH DESIGN AND METHODS: Effects of potential mediators, identified post hoc, on the HR for CV death with empagliflozin versus placebo were analyzed by Cox regression models, with treatment group adjusted for the baseline value of the variable and its change from baseline or updated mean (i.e., considering all prior values), each as a time-dependent covariate. HRs were compared with a model without adjustment for covariates. Multivariable analyses also were performed. RESULTS: Changes in hematocrit and hemoglobin mediated 51.8% and 48.9%, respectively, of the effect of empagliflozin versus placebo on the risk of CV death on the basis of changes from baseline, with similar results in analyses on the basis of updated means. Smaller mediation effects (maximum 29.3%) were observed for uric acid, fasting plasma glucose, and HbA1c. In multivariable models, which incorporated effects of empagliflozin on hematocrit, fasting glucose, uric acid, and urine albumin:creatinine ratio, the combined changes from baseline provided 85.2% mediation, whereas updated mean analyses provided 94.6% mediation of the effect of empagliflozin on CV death. CONCLUSIONS: In this exploratory analysis from the EMPA-REG OUTCOME trial, changes in markers of plasma volume were the most important mediators of the reduction in risk of CV death with empagliflozin versus placebo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both have been identified as important determinants of the heart failure benefits of these drugs in trials of patients with type 2 diabetes.”
From Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial (2021) · cites this paper as [32]
In the citing paper
“Those that appear particularly plausible include effects on volume status, natriuresis, expansion of red blood cell mass, and myocardial energetics (34,36,59,62,64).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [59]
In the citing paper
“Thus, the mechanisms by which SGLT2 inhibitors reduce the risk for HF are not attributable to improved glycemic control (59).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [59]
Citations
Cites
Baron, R. M., & Kenny, D. A. (1986) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.51.6.1173 · Cited by 91,532 · cited 2×
“A traditional mediation analysis as originally proposed by Baron and Kenny (12) was used, taking the time-dynamic evolvement of both the potential mediators and the outcome CV death into account.”
Method(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Introduction to Statistical Mediation Analysis
MacKinnon, D. P. (2012) · doi:10.4324/9780203809556 · Cited by 5,618
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationUric Acid and Cardiovascular Risk
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,440
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Self-citationCherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329 · cited 1×
“Moreover, only variablesmeasured during the trial could be examined, and in addition to the potential mediators we investigated, other variables such as reductions in glomerular hyperfiltration (35), reductions in arterial stiffness and vascular resistance (36), direct cardiac effects through reductions in myocardial…”
BackgroundSelf-citationLow Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155 · cited 1×
“Therefore, many participants in this trial likely had unrecognized left ventricular dysfunction, particularly diastolic dysfunction, which may eventually lead to clinical heart failure with preserved ejection fraction (25).”
Background
Research works printed but not linked: 2
- Fitchett, Further exploration of the cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease in EMPA-REG OUTCOME, J Am Coll Cardiol
- Boehringer Ingelheim. Empagliflozin (Jardiance®) to be studied in chronic kidney disease. 2017. Available from https://www.boehringer-ingelheim.com/press-release/empagliflozin-be-studied-chronic-kidney-disease. Accessed 6 September 2017
Cited by
Zannad, F., Ferreira, J. P., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., Brueckmann, M., Ofstad, A. P., Pfarr, E., Jamal, W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31824-9 · Cited by 1,408
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Cowie, M. R., & Fisher, M. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0406-8 · Cited by 784
Joseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Zelniker, T. A., & Braunwald, E. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.031 · Cited by 566
Verma, S., Mazer, C. D., Yan, A. T., Mason, T., Garg, V., Teoh, H., Zuo, F., Quan, A., Farkouh, M. E., Fitchett, D. H., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042375 · Cited by 572
Self-citationObesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
Lingvay, I., Sumithran, P., Cohen, R. V., & le Roux, C. W. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01919-x · Cited by 581
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Vallon, V., & Verma, S. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-095920 · Cited by 516
“As mentioned above, mediation analyses from EMPA-REG OUTCOME indicated that the rise in hematocrit was a key determinant of the cardiovascular death benefit (80).”
BackgroundMethodSantos-Gallego, C. G., Vargas-Delgado, A. P., Requena-Ibanez, J. A., Garcia-Ropero, A., Mancini, D., Pinney, S., Macaluso, F., Sartori, S., Roque, M., Sabatel-Perez, F., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.008 · Cited by 531
Petrie, M. C., Verma, S., Docherty, K. F., Inzucchi, S. E., Anand, I., Belohlávek, J., Böhm, M., Chiang, C.-E., Chopra, V. K., de Boer, R. A., et al. (2020) · JAMA · doi:10.1001/jama.2020.1906 · Cited by 531
Self-citationMacdougall, I. C., Bircher, A. J., Eckardt, K.-U., Obrador, G. T., Pollock, C. A., Stenvinkel, P., Swinkels, D. W., Wanner, C., Weiss, G., Chertow, G. M., et al. (2016) · Kidney International · doi:10.1016/j.kint.2015.10.002 · Cited by 482
Self-citationHouse, A. A., Wanner, C., Sarnak, M. J., Piña, I. L., McIntyre, C. W., Komenda, P., Kasiske, B. L., Deswal, A., deFilippi, C. R., Cleland, J. G. F., et al. (2019) · Kidney International · doi:10.1016/j.kint.2019.02.022 · Cited by 455
“Kidney International (2019) 95, 1304–1317 to reductions in BP and body weight, promote diuresis, and have strong off-target effects on the cardiac Naþ/Hþ exchanger.(49)”
Self-citationDas, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Januzzi, J. L., Kalyani, R. R., Kosiborod, M., Magwire, M., Morris, P. B., Neumiller, J. J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.037 · Cited by 466
“Interestingly, changes in traditional risk factors such as elevated HbA1C and lipids do not seem to be the key determinants of the beneficial effects of SGLT2 inhibitors on CV and renal outcomes (20,21).”
BackgroundThe tubular hypothesis of nephron filtration and diabetic kidney disease
Vallon, V., & Thomson, S. C. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0256-y · Cited by 465
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Pocock, S. J., Carson, P., Anand, I., Doehner, W., Haass, M., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051783 · Cited by 435
McMurray, J. J. V., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Bengtsson, O., Ponikowski, P., Sabatine, M. S., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1432 · Cited by 433
Self-citationNassif, M. E., Windsor, S. L., Tang, F., Khariton, Y., Husain, M., Inzucchi, S. E., McGuire, D. K., Pitt, B., Scirica, B. M., Austin, B., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042929 · Cited by 424
Self-citationRenoprotective effects of sodium-glucose cotransporter-2 inhibitors
Heerspink, H. J. L., Kosiborod, M., Inzucchi, S. E., & Cherney, D. Z. I. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.027 · Cited by 393
Self-citationDevelopment of SGLT1 and SGLT2 inhibitors
Rieg, T., & Vallon, V. (2018) · Diabetologia · doi:10.1007/s00125-018-4654-7 · Cited by 377
“9%, respectively, of the effect of the SGLT2 inhibitor empagliflozin vs placebo on the risk of cardiovascular death [35].”
Fitchett, D., Inzucchi, S. E., Cannon, C. P., McGuire, D. K., Scirica, B. M., Johansen, O. E., Sambevski, S., Kaspers, S., Pfarr, E., George, J. T., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037778 · Cited by 351
Self-citationFurtado, R. H. M., Bonaca, M. P., Raz, I., Zelniker, T. A., Mosenzon, O., Cahn, A., Kuder, J., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.039996 · Cited by 329
Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Cefalu, W. T., Januzzi, J. L., Kalyani, R. R., Kosiborod, M., Magwire, M. L., Morris, P. B., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.020 · Cited by 300
Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
Scheen, A. J. (2018) · Circulation Research · doi:10.1161/circresaha.117.311588 · Cited by 286
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Di Martino, A., Albanese, G., Di Salvo, J., Epifani, R., Marfella, R., Docimo, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073651 · Cited by 256
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Scheen, A. J. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0392-2 · Cited by 267
Pharmacological treatment of hyperglycemia in type 2 diabetes
Taylor, S. I., Yazdi, Z. S., & Beitelshees, A. L. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142243 · Cited by 245
“Finally, analysis of data from the EMPA-REG OUTCOME trial suggested that increased hematocrit may mediate decreased risk for cardiovascular mortality (42).”
MethodAnker, S. D., Butler, J., Filippatos, G. S., Jamal, W., Salsali, A., Schnee, J., Kimura, K., Zeller, C., George, J., Brueckmann, M., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1596 · Cited by 250
Self-citationPacker, M. (2020) · Diabetes Care · doi:10.2337/dci19-0074 · Cited by 247
“Such a relationship may explainwhy, in statisticalmediation analyses, erythrocytosis has been the most powerful predictor of the action of SGLT2 inhibitors to reduce heart failure events in large-scale trials (44,45).”
BackgroundBrown, A. J. M., Gandy, S., McCrimmon, R., Houston, J. G., Struthers, A. D., & Lang, C. C. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa419 · Cited by 239
“It has been suggested that 50% of the CV benefit seen in the trial could be attributed to empagliflozin induced haemoconcentration.(44) We did not observe any significant change in NT-proBNP but we did observe a significant increase in haematocrit possibly secondary to decreased plasma volume with resultant haemoconce…”
BackgroundHerrington, W. G., Preiss, D., Haynes, R., von Eynatten, M., Staplin, N., Hauske, S. J., George, J. T., Green, J. B., Landray, M. J., Baigent, C., et al. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy090 · Cited by 237
“Exploration of the EMPA-REG OUTCOME data has suggested that the increase in haematocrit caused by empagliflozin, a surrogate for reductions in plasma volume, was the intermediate clinical parameter with the largest mediating effect on the reduction in CV death [85].”
Self-citationCardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes
Zelniker, T. A., & Braunwald, E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.040 · Cited by 236
“, hematocrit and hemoglobin) as the principal mediators contributing to the reduction of cardiovascular death (42).”
BackgroundMustroph, J., Wagemann, O., Lücht, C. M., Trum, M., Hammer, K. P., Sag, C. M., Lebek, S., Tarnowski, D., Reinders, J., Perbellini, F., et al. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12336 · Cited by 225
Shimizu, W., Kubota, Y., Hoshika, Y., Mozawa, K., Tara, S., Tokita, Y., Yodogawa, K., Iwasaki, Y.-K., Yamamoto, T., Takano, H., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01127-z · Cited by 228
Halden, T. A. S., Kvitne, K. E., Midtvedt, K., Rajakumar, L., Robertsen, I., Brox, J., Bollerslev, J., Hartmann, A., Åsberg, A., & Jenssen, T. (2019) · Diabetes Care · doi:10.2337/dc19-0093 · Cited by 231
“It has been speculated that increased hematocrit may mediate a more favorable aerobic metabolism (40).”
BackgroundKraus, B. J., Weir, M. R., Bakris, G. L., Mattheus, M., Cherney, D. Z. I., Sattar, N., Heerspink, H. J. L., Ritter, I., von Eynatten, M., Zinman, B., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.10.031 · Cited by 219
Self-citationSarafidis, P., Ferro, C. J., Morales, E., Ortiz, A., Malyszko, J., Hojs, R., Khazim, K., Ekart, R., Valdivielso, J., Fouque, D., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy407 · Cited by 204
“In mediation analysis, these were key determinants of beneficial cardiovascular outcomes [64].”
BackgroundLee, H.-C., Shiou, Y.-L., Jhuo, S.-J., Chang, C.-Y., Liu, P.-L., Jhuang, W.-J., Dai, Z.-K., Chen, W.-Y., Chen, Y.-F., & Lee, A.-S. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0849-6 · Cited by 204
“There is increase in hematocrit with initial empagliflozin use, but a robust effect on mortality would not be based on oxygen-delivery dynamics at hemoglobin concentration within the normal range [37].”
Backgroundvan Baar, M. J. B., van Ruiten, C. C., Muskiet, M. H. A., van Bloemendaal, L., IJzerman, R. G., & van Raalte, D. H. (2018) · Diabetes Care · doi:10.2337/dc18-0588 · Cited by 199
“In a post hoc analysis of EMPA-REG OUTCOME, plasma volume contraction, estimated by hematocrit concentration, has been put forward (25).”
MethodThe current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
Xu, B., Li, S., Kang, B., & Zhou, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01512-w · Cited by 190
Hesp, A. C., Schaub, J. A., Prasad, P. V., Vallon, V., Laverman, G. D., Bjornstad, P., & van Raalte, D. H. (2020) · Kidney International · doi:10.1016/j.kint.2020.02.041 · Cited by 202
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
Lupsa, B. C., & Inzucchi, S. E. (2018) · Diabetologia · doi:10.1007/s00125-018-4663-6 · Cited by 190
Self-citationCannon, C. P., McGuire, D. K., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Charbonnel, B., Shih, W. J., Gallo, S., Masiukiewicz, U., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.08.016 · Cited by 203
Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
Bonora, B. M., Avogaro, A., & Fadini, G. P. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s233538 · Cited by 177
“The other mediators had no effects in these analyses.(89)”
Berg, D. D., Jhund, P. S., Docherty, K. F., Murphy, S. A., Verma, S., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.7585 · Cited by 189
Self-citationIkonomidis, I., Pavlidis, G., Thymis, J., Birba, D., Kalogeris, A., Kousathana, F., Kountouri, A., Balampanis, K., Parissis, J., Andreadou, I., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015716 · Cited by 199
SGLT2 inhibition and kidney protection
Nespoux, J., & Vallon, V. (2018) · Clinical Science · doi:10.1042/cs20171298 · Cited by 172
“This may explain why effects of SGLT2 inhibitors on volume status rather than HbA1c levels were the most important mediators reducing the risk of CV death [44].”
BackgroundSeferović, P. M., Coats, A. J. S., Ponikowski, P., Filippatos, G., Huelsmann, M., Jhund, P. S., Polovina, M. M., Komajda, M., Seferović, J., Sari, I., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1673 · Cited by 178
Packer, M. (2020) · Circulation: Heart Failure · doi:10.1161/circheartfailure.120.007197 · Cited by 176
Buse, J. B., Bain, S. C., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Pratley, R. E., Linder, M., Monk Fries, T., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2251 · Cited by 175
“(11) with the intention of capturing the cumulative effect of all prior values of the mediator on the outcome, in contrast to the acute effect in the first approach above.”
BackgroundMethodInfluentialSelf-citationPharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 184
Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes
Matsutani, D., Sakamoto, M., Kayama, Y., Takeda, N., Horiuchi, R., & Utsunomiya, K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0717-9 · Cited by 168
“Also, a recent sub-analysis in the EMPA-REG trial indicated that Hb increases were involved in suppression of cardiovascular events independently of lowered plasma glucose and decreased BP, suggesting the involvement of improved left ventricular diastolic function via rises in Hb [54].”
BackgroundThe New Biology of Diabetic Kidney Disease—Mechanisms and Therapeutic Implications
Lytvyn, Y., Bjornstad, P., van Raalte, D. H., Heerspink, H. L., & Cherney, D. Z. I. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz010 · Cited by 165
Ku, E., Vecchio, L. D., Eckardt, K., Haase, V. H., Johansen, K. L., Nangaku, M., Tangri, N., Waikar, S. S., Więcek, A., Cheung, M., et al. (2023) · Kidney International · doi:10.1016/j.kint.2023.05.009 · Cited by 182
Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control
Inzucchi, S. E., Kosiborod, M., Fitchett, D., Wanner, C., Hehnke, U., Kaspers, S., George, J. T., & Zinman, B. (2018) · Circulation · doi:10.1161/circulationaha.118.035759 · Cited by 162
Self-citationEmpagliflozin: A Review in Type 2 Diabetes
Frampton, J. E. (2018) · Drugs · doi:10.1007/s40265-018-0937-z · Cited by 171
“reductions in plasma volume, BP and arterial stiffness) may be the main mediator of CV benefit [5, 47, 81, 82]; in addition to systemic haemodynamic changes, direct renal haemodynamic effects that reduce glomerular hyperfiltration may be important mediator of renal benefit [41]”
BackgroundGlucose transporters in the kidney in health and disease
Vallon, V. (2020) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-020-02361-w · Cited by 161
“Notably, 52 and 49% of the effect of the SGLT2 inhibitor empagliflozin on the risk of cardiovascular death was explained by changes in hematocrit and hemoglobin from baseline, respectively [71].”
BackgroundBadura, K., Janc, J. J., Wąsik, J., Gnitecki, S., Skwira, S., Młynarska, E., Rysz, J., & Franczyk, B. (2024) · Biomedicines · doi:10.3390/biomedicines12061191 · Cited by 203
“Although SGLT-2i have been primarily studied for their effects on glycemic control and cardiovascular outcomes in patients with diabetes, they have been shown to increase Hb in patients with kidney disease and/or heart failure [143–145].”
BackgroundSGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback
Upadhyay, A. (2024) · Kidney360 · doi:10.34067/kid.0000000000000425 · Cited by 166
“48 Interestingly, however, improvement in renal cortical oxygenation occurred without an increase in cortical perfusion or oxygen delivery in a trial involving participants with type 1 DM. 43 This observation suggests that SGLT2 inhibition may be improving kidney oxygenation in this trial by…”
BackgroundMediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
Li, J., Woodward, M., Perkovic, V., Figtree, G. A., Heerspink, H. J. L., Mahaffey, K. W., de Zeeuw, D., Vercruysse, F., Shaw, W., Matthews, D. R., et al. (2020) · JACC: Heart Failure · doi:10.1016/j.jchf.2019.08.004 · Cited by 144
“Those analyses concluded that effects on plasma volume were the most important mediators of effect but also highlighted the role of changes in FPG, UACR, and uric acid (8).”
BackgroundMethodInfluentialQuerfeld, U., MAK, R. H. K., & Pries, A. R. (2020) · Clinical Science · doi:10.1042/cs20200279 · Cited by 152
Diabetic cardiomyopathy: prevalence, determinants and potential treatments
Gulsin, G. S., Athithan, L., & McCann, G. P. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819834869 · Cited by 157
SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?
Pabel, S., Hamdani, N., Luedde, M., & Sossalla, S. T. (2021) · Current Heart Failure Reports · doi:10.1007/s11897-021-00529-8 · Cited by 152
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
Gerstein, H. C., Hart, R., Colhoun, H. M., Diaz, R., Lakshmanan, M., Botros, F. T., Probstfield, J., Riddle, M. C., Rydén, L., Atisso, C. M., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30423-1 · Cited by 137
Tuttle, K. R., Brosius, F. C., Cavender, M. A., Fioretto, P., Fowler, K. J., Heerspink, H. J. L., Manley, T., McGuire, D. K., Molitch, M. E., Mottl, A. K., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.08.003 · Cited by 142
Self-citationSeferovic, P. M., Fragasso, G., Petrie, M. C., Müllens, W., Ferrari, R., Thum, T., Bauersachs, J. K., Anker, S. D., Ray, R., Çavuşoğlu, Y., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1954 · Cited by 142
Oshima, M., Neuen, B. L., Jardine, M. J., Bakris, G., Edwards, R., Levin, A., Mahaffey, K. W., Neal, B., Pollock, C., Rosenthal, N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30300-4 · Cited by 135
Schwaiger, E., Burghart, L., Signorini, L., Ristl, R., Kopecky, C., Tura, A., Pacini, G., Wrba, T., Antlanger, M., Schmaldienst, S., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15223 · Cited by 133
Bosch, A., Ott, C., Jung, S., Striepe, K., Karg, M. V., Kannenkeril, D., Dienemann, T., & Schmieder, R. E. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0839-8 · Cited by 125
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes
Li, J., Neal, B., Perkovic, V., de Zeeuw, D., Neuen, B. L., Arnott, C., Simpson, R., Oh, R., Mahaffey, K. W., & Heerspink, H. J. L. (2020) · Kidney International · doi:10.1016/j.kint.2020.04.051 · Cited by 130
“Markers of volume status, including hematocrit and hemoglobin, have been reported previously to be strong mediators of the beneficial effects of SGLT2 inhibitors on cardiovascular death and heart failure hospitalization.(9,11) Fluid overload has been associated with a higher risk of end-stage kidney disease in observa…”
BackgroundDoehner, W., Anker, S. D., Butler, J., Zannad, F. M., Filippatos, G. S., Ferreira, J. P., Salsali, A., Kaempfer, C., Brueckmann, M., Pocock, S., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac320 · Cited by 129
Cardiorenal protection of SGLT2 inhibitors—Perspectives from metabolic reprogramming
Gao, Y.-M., Feng, S., Wen, Y., Tang, T., Wang, B., & Liu, B. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104215 · Cited by 131
Connelly, K. A., Zhang, Y., Visram, A., Advani, A., Batchu, S. N., Desjardins, J.-F., Thai, K., & Gilbert, R. E. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.11.010 · Cited by 120
“Although at first these findings appeared incongruous to the functional improvements seen, they were in keeping with data from a wide body of investigators who demonstrated that most of benefits in rodents occurred from the hemodynamic effects and hemoconcentration, and not from altered energetics as a result of keton…”
ResultPacker, M. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020010010 · Cited by 123
Scholtes, R. A., Muskiet, M. H. A., van Baar, M. J. B., Hesp, A. C., Greasley, P. J., Karlsson, C., Hammarstedt, A., Arya, N., van Raalte, D. H., & Heerspink, H. J. L. (2021) · Diabetes Care · doi:10.2337/dc20-2604 · Cited by 125
“including volume contraction secondary to glycosuria and natriuresis, leading to reduced cardiac pre- and afterload (6,7).”
BackgroundImpact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
Palmiero, G., Cesaro, A., Vetrano, E., Pafundi, P. C., Galiero, R., Caturano, A., Moscarella, E., Gragnano, F., Salvatore, T., Rinaldi, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115863 · Cited by 110
“Besides, the observed relationship between increased hemoglobin and hematocrit levels and cardioprotection after the administration of Empagliflozin (shown in the exploratory analysis of the EMPA-REG study) was associated with a decrease in the CV mortality rate [133].”
BackgroundDiabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists
Wilcox, T., De Block, C., Schwartzbard, A. Z., & Newman, J. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.056 · Cited by 112
“Further evidence of hemodynamic benefit is suggested by a recent mediation analysis from EMPA-REG showing that markers of plasma volume such as hematocrit and hemoglobin were important markers associated with reduction in cardiovascular mortality observed with SGLT2i use (10,78).”
BackgroundMethodTuttle, K. R., Brosius, F. C., Cavender, M. A., Fioretto, P., Fowler, K. J., Heerspink, H. J. L., Manley, T., McGuire, D. K., Molitch, M. E., Mottl, A. K., et al. (2021) · Diabetes · doi:10.2337/dbi20-0040 · Cited by 123
“Those that appear particularly plausible include effects on volume status, natriuresis, expansion of red blood cell mass, and myocardial energetics (34,36,59,62,64).”
BackgroundSelf-citationAnti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin
Grotta, R. L., de Candia, P., Olivieri, F., Matacchione, G., Giuliani, A., Rippo, M. R., Tagliabue, E., Mancino, M., Rispoli, F., Ferroni, S., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04289-z · Cited by 124
“On the contrary, uric acid was suggested to mediate part of the beneficial effect of empagliflozin on CV and kidney-related endpoints in the EMPA-REG trial [12].”
BackgroundJaved, Z., Papageorgiou, M., Deshmukh, H., Rigby, A. S., Qamar, U., Abbas, J., Khan, A. Y., Kilpatrick, E. S., Atkin, S. L., & Sathyapalan, T. (2019) · Clinical Endocrinology · doi:10.1111/cen.13968 · Cited by 121
State-of-the-Art-Review: Mechanisms of Action of SGLT2 Inhibitors and Clinical Implications
Vallon, V. (2024) · American Journal of Hypertension · doi:10.1093/ajh/hpae092 · Cited by 135
Perry, R. J., & Shulman, G. I. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.008387 · Cited by 147
“In addition, most studies (107, 112, 113, 121), with one exception (122), indicated that hemoglobin A1c did not correlate with cardiovascular outcomes in those treated with an SGLT2 inhibitor, and cardiovascular benefits were observed in nondiabetic humans (110) and rodents (123–125).”
BackgroundCardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?
Elrakaybi, A., Laubner, K., Zhou, Q., Hug, M. J., & Seufert, J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101549 · Cited by 124
“SGLT2 inhibitors have been shown to reduce the levels of circulating uric acid regardless of diabetic status [130,131] and in patients with CV risk [27,132].”
BackgroundPrattichizzo, F., De Nigris, V., Micheloni, S., La Sala, L., & Ceriello, A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13488 · Cited by 116
El-Daly, M., Pulakazhi Venu, V. K., Saifeddine, M., Mihara, K., Kang, S., Fedak, P. W. M., Alston, L. A., Hirota, S. A., Ding, H., Triggle, C. R., et al. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2018.06.006 · Cited by 117
Management of post‐transplant diabetes: immunosuppression, early prevention, and novel antidiabetics
Hecking, M., Sharif, A., Eller, K., & Jenssen, T. G. (2020) · Transplant International · doi:10.1111/tri.13783 · Cited by 125
Giugliano, D., Longo, M., Scappaticcio, L., Bellastella, G., Maiorino, M. I., & Esposito, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01430-3 · Cited by 107
“However, once their efficacy in reducing the risk of heart failure or progression of chronic kidney disease was ascertained [3–6] and thought to be largely independent of baseline and time-dependent changes in glycated hemoglobin [7], the hypothesis emerged that their cardiorenal benefits might not necessarily be due…”
BackgroundPacker, M. (2020) · Circulation · doi:10.1161/circulationaha.119.045561 · Cited by 115
Packer, M. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01041-4 · Cited by 116
Jensen, J., Omar, M., Kistorp, C., Poulsen, M. K., Tuxen, C., Gustafsson, I., Køber, L., Gustafsson, F., Faber, J. O., Fosbøl, E. L., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.07.011 · Cited by 116
Salah, H. M., Al'Aref, S. J., Khan, M. S., Al-Hawwas, M., Vallurupalli, S., Mehta, J. L., Mounsey, J. P., Greene, S. J., McGuire, D. K., Lopes, R. D., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2020.10.064 · Cited by 110
Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular Disease
Katsiki, N., Dimitriadis, G., & Mikhailidis, D. P. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210104124320 · Cited by 118
Perry, R. J., Rabin-Court, A., Song, J. D., Cardone, R. L., Wang, Y., Kibbey, R. G., & Shulman, G. I. (2019) · Nature Communications · doi:10.1038/s41467-019-08466-w · Cited by 105
Sharma, A., Pagidipati, N. J., Califf, R. M., McGuire, D. K., Green, J. B., Demets, D., George, J. T., Gerstein, H. C., Hobbs, T., Holman, R. R., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.041022 · Cited by 110
Self-citationSGLT2-inhibitors; more than just glycosuria and diuresis
Fathi, A., Vickneson, K., & Singh, J. S. (2021) · Heart Failure Reviews · doi:10.1007/s10741-020-10038-w · Cited by 109
“fact, a mediation analysis of the EMPA-REG OUTCOME showed changes in haemoglobin and haematocrit were responsible for approximately 50% of the risk reduction in CV death in that trial [108].”
MethodSGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses
Filippatos, T. D., Liontos, A., Papakitsou, I., & Elisaf, M. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1581971 · Cited by 117
“Interestingly, an exploratory analysis of the EMPA-REG OUTCOME trial showed that the increases in hematocrit and hemoglobin were the most important mediators of CV mortality reduction with empagliflozin administration [21].”
MethodDekkers, C. C. J., Sjöström, C. D., Greasley, P. J., Cain, V., Boulton, D. W., & Heerspink, H. J. L. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13855 · Cited by 106
“and haemoglobin are important mediators of the reduction in cardiovascular mortality observed in the EMPAREG trial.(7) To extend the initial findings of the effects of dapagliflozin on”
BackgroundMutual Antagonism of Hypoxia-Inducible Factor Isoforms in Cardiac, Vascular, and Renal Disorders
Packer, M. (2020) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2020.05.006 · Cited by 107
“The importance of this latter effect is reinforced by the results of statistical mediation analyses, which showed that changes in hemoglobin produced by SGLT2 inhibitors are a powerful predictor of their ability to reduce the risk of cardiovascular death and hospitalizations for heart failure (101,102).”
Result
Metadata
- Authors
- Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., Hantel, S., Bluhmki, E., & Lachin, J. M.
- Affiliations
- Yale University (US)
- Mount Sinai Hospital (CA)
- St. Michael's Hospital (CA)
- Universitätsklinikum Würzburg (DE)
- Istituto di Fisiologia Clinica (IT)
- University of Freiburg (DE)
- Boehringer Ingelheim (Norway) (NO)
- Boehringer Ingelheim (Germany) (DE)
- George Washington University (US)
- Corresponding author
- Inzucchi, Silvio E.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-12-04
- Volume
- 41
- Issue
- 2
- Pages
- 356-363
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2772204795
- Cited by
- 740
- References
- 33
- Citations by year
- 2026: 33 · 2025: 48 · 2024: 71 · 2023: 83 · 2022: 103 · 2021: 109 · 2020: 139 · 2019: 96 · 2018: 56
- FWCI
- 62.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Eisai
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- empagliflozin, cardiovascular mortality, mediation analysis, type 2 diabetes, EMPA-REG OUTCOME trial, hematocrit, hemoglobin, plasma volume, uric acid, fasting blood glucose, HbA1c, urine albumin-creatinine ratio, SGLT2 inhibitors
- MeSH terms
- Adult, Aged, Benzhydryl Compounds, Blood Glucose, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Dose-Response Relationship, Drug, Female, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Placebos, Risk Factors, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.